All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

MOMENTUM trial: Updates from ASH 2022

Jan 13, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in myelofibrosis.

The pivotal phase III MOMENTUM study (NCT04173494) was designed to confirm the differentiated clinical benefits of momelotinib versus danazol in anemic patients with symptomatic myelofibrosis (MF) previously treated with a JAK inhibitor.1

The MPN Hub previously reported on updates from the MOMENTUM trial presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, where the study design and 24-week outcomes can be reviewed. Of note, ~50% of patients were transfusion dependent at baseline, with a further 35% of patients receiving some transfusions.1

Here, we summarize updated efficacy and safety data presented by Aaron Gerds at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition following the completion of all patients’ 48-week assessments, including data specific to patients with thrombocytopenia.1

TSS, TI, and spleen responses at Week 48

The 24-week total symptom score (TSS), transfusion independence (TI), and spleen responses were sustained at Week 48 (Table 1).

Table 1. TSS, TI, and spleen responses at Week 48

Response, %

Momelotinib continued

Danazol crossover to momelotinib

TSS

 

 

                 At Week 24

25

9

    Maintained at Week 48

97

100

TI

 

 

              At Week 24

31

20

              Maintained at Week 48

90

77

SRR35

 

 

              At Week 24

23

3

              Maintained at Week 28

100

100

SRR35, splenic response rate with a 35% reduction; TI, transfusion independence; TSS, total symptom score.
*Adapted from Gerds.1

Of non-responders at Week 24, 29% of patients treated with danazol who switched to momelotinib were new responders by Week 48, as were 20% of momelotinib non-responders. These results indicate that a longer duration of therapy may be beneficial for patients treated with momelotinib.

Overall survival and leukemia-free survival at Week 48

Overall survival (OS) and leukemia-free survival curves converged for patients who continued momelotinib treatment or switched from danazol to momelotinib at Week 24. For patients who remained on momelotinib, OS was significantly improved at Week 48 for those who achieved a TI response at Week 24.

Efficacy results in patients with thrombocytopenia (platelets <100 × 109/L) were consistent with the general study population. In subsets of patients with thrombocytopenia, improved OS benefit was seen in patients with baseline platelets (<50 × 109/L) for momelotinib versus danazol. However, study numbers were small, warranting further investigation.

Safety at Week 48

Grade ≥3 and serious adverse event rates at 48 weeks were comparable between the two arms (Table 2).

Table 2. Grade ≥3 and serious adverse event rates at 48 weeks*

TEAE, %

Momelotinib continued

Danazol crossover to momelotinib

Grade ≥3 AEs

49.5

46.3

SAEs

31.2

29.3

AE, adverse event; SAE, serious adverse event; TEAE, treatment-emergent adverse event.
*Adapted from Gerds.1

  • No new safety signals were detected.
  • Rates of peripheral neuropathy were very low in both arms (2.2% for momelotinib continuation and 2.4% for danazol to momelotinib).
  • Safety in patients with thrombocytopenia (platelets <100 × 109/L) were consistent with the general study population.

Conclusion

In this updated analysis, momelotinib maintained 24-week symptom, TI, and spleen responses at Week 48 in symptomatic and anemic patients with MF, with favorable survival and safety outcomes. The study reports sustained TSS response at Week 48 and new TSS responses beyond Week 24. Efficacy and safety results in patients with thrombocytopenia were consistent with those of the general study population. These findings indicate that momelotinib may address a critical unmet need in patients with MF and anemia, including those with severe thrombocytopenia.

  1. Gerds A. Updated results from the momentum phase 3 study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor. Oral abstract #627. 64th American Society of Hematology Annual Meeting and Exposition; Dec 11, 2022; New Orleans, US.